Publications by authors named "Juan Pablo Perez-Wert"
Clin Genitourin Cancer
August 2022
Article Synopsis
- Docetaxel is standardly administered at 75 mg/m every 3 weeks for metastatic prostate cancer, but a lower dose of 50 mg/m every 2 weeks may be better for frail patients.
- A retrospective study of 200 patients revealed that those on the 2-weekly schedule were older and had more health issues, but it didn't significantly impact survival when accounting for other factors.
- While the 2-week schedule had more treatment delays and suspensions, it led to fewer severe toxicities, suggesting it could be a viable option for older, frailer patients.
